FindTrial
Sign In

Safety of tranexamic acid in thrombotic adverse events and seizure in hemorrhagic patients: a systematic review and meta-analysis

Safety of tranexamic acid in thrombotic adverse events and seizure in hemorrhagic patients: a systematic review and meta-analysis - Safety of tranexamic acid in thrombotic adverse events and seizure in hemorrhagic patients: a systematic review and meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000039611
Enrollment
10000
Registered
2020-02-26
Start date
2020-01-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with bleeding in any underlying disease

Interventions

None listed

Sponsors

Osaka General Medical Center, Division of Trauma and Surgical Critical Care
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: We will include patients administered TXA for any underlying disease such as trauma, surgery, post-partum hemorrhage, spontaneous intracranial hemorrhage, and gastrointestinal hemorrhage.

Exclusion criteria

Exclusion criteria: Studies done with animals will be excluded from this review.

Design outcomes

Primary

MeasureTime frame
The occurrence of any thrombotic adverse events, including acute coronary syndrome (ACS), stroke/transient ischemic attack (TIA), and venous thromboembolism (VTE), and seizure.—

Secondary

MeasureTime frame
The occurrence of ACS, stroke/TIA, and VTE will be assessed separately.—

Countries

Japan

Contacts

Public ContactKazuma Yamakawa

Osaka General Medical Center Division of Trauma and Surgical Critical Care

k.yamakawa0911@gmail.com+81-6-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026